Gary Jacob

The U.S. Food and Drug Administration said it approved Synergy Pharmaceuticals Inc's (NASDAQ: SGYP) plecanatide, branded as Trulance, for the treatment of chronic idiopathic constipation (CIC). This approval marks the company’s first. Trulance is a one-tablet-a-day drug used to treat...

Before Friday's market open, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced positive data from its first of two Phase 3 trials for clinical constipation-predominant irritable bowel syndrome (IBS-C) drug plecanatide. “We are very pleased with these results,” said Gary S. Jacob,...